Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One

In this issue of , Pullarkat and colleagues present the results from a phase I clinical trial that is the first to combine small-molecule inhibitors for multiple antiapoptotic proteins, BCL2 as well as BCL-X , with a traditional chemotherapy backbone for patients with relapsed/refractory acute lymph...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer discovery 2021-06, Vol.11 (6), p.1324-1326
Hauptverfasser:	Larkin, Karilyn T M, Byrd, John C
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis bcl-X Protein - genetics Humans Neoplasms Sulfonamides
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	1326
container_issue	6
container_start_page	1324
container_title	Cancer discovery
container_volume	11
creator	Larkin, Karilyn T M Byrd, John C
description	In this issue of , Pullarkat and colleagues present the results from a phase I clinical trial that is the first to combine small-molecule inhibitors for multiple antiapoptotic proteins, BCL2 as well as BCL-X , with a traditional chemotherapy backbone for patients with relapsed/refractory acute lymphoblastic leukemia. This trial has demonstrated impressive response rates with acceptable toxicity while providing proof of concept that dual targeting-hitting BCL2 hard and BCL-X soft-is both effective and tolerable in a heterogeneous patient population with prior existing cytopenias. .
doi_str_mv	10.1158/2159-8290.CD-21-0261
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2536800380</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2536800380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c302t-281a63e6536e1c6bb1f02bb29b6b1ea4a13c8c4a41df0cc68b7c40afe037c82e3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EohX0DxDykk2KX3EcdiXlUalSN0EsLdudNEFtXOxUiL8nUUtnM3NHd-5IB6E7SqaUpuqR0TRPFMvJtJgnjCaESXqBxuf15XnOxAhNYvwifYlcpCS7RiMuSKakpGO0XLR1Y5uuaTe4qwGfpA8R-wrP9n7f-djEJ_xZQ4vLH49LEzbQRTwLgJ-h6yDgsjYtXrVwi64qs40wOfUb9PH6UhbvyXL1tihmy8RxwrqEKWokB5lyCdRJa2lFmLUst9JSMMJQ7pQTRtB1RZyTymZOEFMB4ZlTDPgNejjm7oP_PkDs9K6JDrZb04I_RM36ZEUIV6S3iqPVBR9jgErvQ7Mz4VdTogeUeuCkB2a6mPdCDyj7s_vTh4Pdwfp89A-O_wFi824A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2536800380</pqid></control><display><type>article</type><title>Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Larkin, Karilyn T M ; Byrd, John C</creator><creatorcontrib>Larkin, Karilyn T M ; Byrd, John C</creatorcontrib><description>In this issue of , Pullarkat and colleagues present the results from a phase I clinical trial that is the first to combine small-molecule inhibitors for multiple antiapoptotic proteins, BCL2 as well as BCL-X , with a traditional chemotherapy backbone for patients with relapsed/refractory acute lymphoblastic leukemia. This trial has demonstrated impressive response rates with acceptable toxicity while providing proof of concept that dual targeting-hitting BCL2 hard and BCL-X soft-is both effective and tolerable in a heterogeneous patient population with prior existing cytopenias. .</description><identifier>ISSN: 2159-8274</identifier><identifier>EISSN: 2159-8290</identifier><identifier>DOI: 10.1158/2159-8290.CD-21-0261</identifier><identifier>PMID: 34078661</identifier><language>eng</language><publisher>United States</publisher><subject>Apoptosis ; bcl-X Protein - genetics ; Humans ; Neoplasms ; Sulfonamides</subject><ispartof>Cancer discovery, 2021-06, Vol.11 (6), p.1324-1326</ispartof><rights>2021 American Association for Cancer Research.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c302t-281a63e6536e1c6bb1f02bb29b6b1ea4a13c8c4a41df0cc68b7c40afe037c82e3</cites><orcidid>0000-0002-1898-9836</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3356,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34078661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Larkin, Karilyn T M</creatorcontrib><creatorcontrib>Byrd, John C</creatorcontrib><title>Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One</title><title>Cancer discovery</title><addtitle>Cancer Discov</addtitle><description>In this issue of , Pullarkat and colleagues present the results from a phase I clinical trial that is the first to combine small-molecule inhibitors for multiple antiapoptotic proteins, BCL2 as well as BCL-X , with a traditional chemotherapy backbone for patients with relapsed/refractory acute lymphoblastic leukemia. This trial has demonstrated impressive response rates with acceptable toxicity while providing proof of concept that dual targeting-hitting BCL2 hard and BCL-X soft-is both effective and tolerable in a heterogeneous patient population with prior existing cytopenias. .</description><subject>Apoptosis</subject><subject>bcl-X Protein - genetics</subject><subject>Humans</subject><subject>Neoplasms</subject><subject>Sulfonamides</subject><issn>2159-8274</issn><issn>2159-8290</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRS0EohX0DxDykk2KX3EcdiXlUalSN0EsLdudNEFtXOxUiL8nUUtnM3NHd-5IB6E7SqaUpuqR0TRPFMvJtJgnjCaESXqBxuf15XnOxAhNYvwifYlcpCS7RiMuSKakpGO0XLR1Y5uuaTe4qwGfpA8R-wrP9n7f-djEJ_xZQ4vLH49LEzbQRTwLgJ-h6yDgsjYtXrVwi64qs40wOfUb9PH6UhbvyXL1tihmy8RxwrqEKWokB5lyCdRJa2lFmLUst9JSMMJQ7pQTRtB1RZyTymZOEFMB4ZlTDPgNejjm7oP_PkDs9K6JDrZb04I_RM36ZEUIV6S3iqPVBR9jgErvQ7Mz4VdTogeUeuCkB2a6mPdCDyj7s_vTh4Pdwfp89A-O_wFi824A</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Larkin, Karilyn T M</creator><creator>Byrd, John C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1898-9836</orcidid></search><sort><creationdate>20210601</creationdate><title>Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One</title><author>Larkin, Karilyn T M ; Byrd, John C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c302t-281a63e6536e1c6bb1f02bb29b6b1ea4a13c8c4a41df0cc68b7c40afe037c82e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Apoptosis</topic><topic>bcl-X Protein - genetics</topic><topic>Humans</topic><topic>Neoplasms</topic><topic>Sulfonamides</topic><toplevel>online_resources</toplevel><creatorcontrib>Larkin, Karilyn T M</creatorcontrib><creatorcontrib>Byrd, John C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Larkin, Karilyn T M</au><au>Byrd, John C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One</atitle><jtitle>Cancer discovery</jtitle><addtitle>Cancer Discov</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>11</volume><issue>6</issue><spage>1324</spage><epage>1326</epage><pages>1324-1326</pages><issn>2159-8274</issn><eissn>2159-8290</eissn><abstract>In this issue of , Pullarkat and colleagues present the results from a phase I clinical trial that is the first to combine small-molecule inhibitors for multiple antiapoptotic proteins, BCL2 as well as BCL-X , with a traditional chemotherapy backbone for patients with relapsed/refractory acute lymphoblastic leukemia. This trial has demonstrated impressive response rates with acceptable toxicity while providing proof of concept that dual targeting-hitting BCL2 hard and BCL-X soft-is both effective and tolerable in a heterogeneous patient population with prior existing cytopenias. .</abstract><cop>United States</cop><pmid>34078661</pmid><doi>10.1158/2159-8290.CD-21-0261</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-1898-9836</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2159-8274
ispartof	Cancer discovery, 2021-06, Vol.11 (6), p.1324-1326
issn	2159-8274 2159-8290
language	eng
recordid	cdi_proquest_miscellaneous_2536800380
source	MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects	Apoptosis bcl-X Protein - genetics Humans Neoplasms Sulfonamides
title	Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A56%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibiting%20the%20Inhibitors%20of%20Apoptosis:%20When%20Two%20Targets%20Are%20Better%20Than%20One&rft.jtitle=Cancer%20discovery&rft.au=Larkin,%20Karilyn%20T%20M&rft.date=2021-06-01&rft.volume=11&rft.issue=6&rft.spage=1324&rft.epage=1326&rft.pages=1324-1326&rft.issn=2159-8274&rft.eissn=2159-8290&rft_id=info:doi/10.1158/2159-8290.CD-21-0261&rft_dat=%3Cproquest_cross%3E2536800380%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2536800380&rft_id=info:pmid/34078661&rfr_iscdi=true